Clinical Trial Update: Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of dalantercept combined with sorafenib in advanced hepatocellular carcinoma has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sorafenib (Sorafenib)
• dalantercept (dalantercept)

Snippet

Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Conditions: Advanced Adult Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-12-22